Cardiac toxicity is an uncommon but potentially serious complication of high-dose (HD) chemotherapy and little is known about incidence, severity and underlying mechanisms. We have systematically reviewed the literature of the last 30 years to summarize and appraise the published evidence on cardiac toxicity associated with HD chemotherapy. HD cyclophosphamide-containing regimens have been most commonly associated with cardiac toxicity, with a progressively decreasing incidence over time. Dosage, application regimens and coadministration of other chemotherapeutic agents emerged as risk factors. While cardiac toxicity has been rarely associated with other cytotoxic drugs, an unexpected incidence of severe cardiotoxicity resulted from reduced-intensity conditioning regimens containing melphalan and fludarabine. Predictive value of cardiologic examination of patients is limited, and patients with a slight depression of cardiac performance could tolerate HD chemotherapy. Clinical examination, resting electrocardiography and dosage adjustment in overweight patients remain the mainstay of prevention, with bidimensional echocardiography (2D echo) for patients with a history of anthracycline exposure. Strategies to decrease the long-term negative impact of anthracycline administration on cardiac performance are being investigated. New 2D echo-based techniques and circulating markers of cardiac function hold promise for allowing identification of patients at high risk for and early diagnosis of cardiac toxicity.
Introduction of high-dose (HD) chemotherapy followed by hematopoietic stem cell (HSC) transplantation has improved the clinical outcome for selected groups of patients with chemosensitive tumors, such as non-Hodgkin's lymphoma, Hodgkin's disease, multiple myeloma, leukemias, breast cancer and germ cell tumors. 1, 2 Moreover, HD melphalan and HD cyclophosphamide have been successfully used to treat primary amyloidosis 3 and autoimmune diseases, 4, 5 respectively. Finally, in the last few years reduced-intensity conditioning regimens have been applied to patients undergoing allogeneic HSC transplantation to reduce drug toxicity while maintaining the potential for achieving disease remission exploiting the graft-versus-leukemia effect. 6 Cardiac complications have been documented in several series, with reported incidence varying among investigators from 0 4, 5, [7] [8] [9] to 43%, 10 and mortality up to 9% 10 in earlier studies. Although HD chemotherapy-associated cardiac toxicity has become less common in recent years using current preparative regimens, high incidence of severe cardiac toxicity, including toxic death, is still being reported in some series.
Despite thousands of patients having been treated, pharmacokinetic/dynamic variables, identification of risk factors and definition of cost-effective strategies for cardiologic evaluation of HD chemotherapy candidates and subsequent monitoring have not been established yet. This lack of knowledge has important clinical implications, as in some instances, toxicity to the cardiovascular system may be the dose-limiting factor in determining the treatment regimen.
Therefore, we have scanned the literature from the last 30 years (using the PubMed database and lateral references) in order to provide a systematic overview of the general features of cardiotoxic effects of HD chemotherapy and nonmyeloablative HSC transplantation and an approach to their diagnosis, management and prevention. Knowledge gained from our own personal experience has been used to supplement the many gaps in the literature.
Cardiac toxicity due to conditioning regimen
Cyclophosphamide A wide variety of HD chemotherapy regimens have been used, and cardiac toxicity has been associated mostly with HD cyclophosphamide-containing regimens. Since its initial description 30 years ago, 11 it has been reported by many others, 10, [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] with a wide spectrum of incidence, manifestation and severity. 10, [12] [13] [14] [15] [16] [20] [21] [22] [23] On the basis of postmortem examination, [10] [11] [12] 14, 15, 20, 21, 24 the pathophysiology of HD cyclophosphamide-associated cardiac toxicity is thought to depend upon toxic endothelial damage followed by extravasation of toxic metabolites with resultant myocyte damage and interstitial hemorrhage and edema. HD cyclophosphamide-associated cardiotoxicity occurs during or soon after (within 3 weeks) administration. It is manifested clinically as acute or subacute onset of congestive heart failure (CHF) with pulmonary congestion, weight gain and oliguria. Pericardial effusion, in some cases with cardiac tamponade, may be part of the clinical picture 10, 12, 14, 15 or the only manifestation of cardiac toxicity. 10, 15, 18, 22, 24 Although HD cyclophosphamide-associated cardiac toxicity is potentially reversible, in patients who develop severe, progressive CHF, this complication may lead to death within few weeks.
Studies from the 1970s and 1980s using combination regimens reported an incidence up to 43%. 10 However, in recent years, the percentage of patients receiving singleagent HD cyclophosphamide up to 7 g/m 2 or 200 mg/kg experiencing cardiotoxicity has diminished to nearly zero with the adoption of multifractionated schedule of administration. 4, 5, [7] [8] [9] 25 Available evidence indicates that singleagent HD cyclophosphamide-associated cardiac toxicity is dose and schedule dependent, and it is not related to the cumulative drug dose. 13, 16, 21 No pharmacokinetic parameter has been consistently associated with cardiotoxicity, although a significant inverse association between a reduced HD cyclophosphamide area under the curve (AUC) (ie accelerated clearance due to an increased conversion to active metabolites) and cardiotoxicity was found in three independent studies, 17, 26, 27 but not confirmed in a larger one. 28 A common finding in these studies has been a considerable interpatient variation in the AUC, raising the possibility that such variability could produce differences in the pharmacodynamic outcome. The pathways of drug clearance or inactivation exhibit polymorphic differences. Interindividual, race-specific and age-related responses to chemotherapeutic agents are common. Genetic variants in the drug target itself, disease pathway genes or drug-metabolizing enzymes may all be used as predictors of drug efficacy or toxicity. A DNA-based approach focused on predicting of toxic responses to drugs and selecting the best individual and combinations of anticancer drugs would shift the current prescribing paradigm from its empirical nature to a more patient-specific model. 29 
Combinations including cyclophosphamide
Several widely employed combinations of HD cyclophosphamide are not associated with an increased risk of cardiotoxicity over single-agent HD cyclophosphamide. 26, 28, [30] [31] [32] [33] [34] [35] However, the risk for HD cyclophosphamide-associated cardiac toxicity may be increased by the concomitant administration of cytarabine or mitoxantrone.
Cytarabine
Administration of HD cytarabine has been associated with both cardiac arrhythmias 36, 37 and pericarditis. 38 However, the highest incidence and severity of cardiac toxicity was reported when the two drugs were coadministered in different combination regimens, 10, 12, 14, 15, 20, [39] [40] [41] [42] with the partial exception of the BEAC (carmustine, etoposide, cytarabine, cyclophosphamide) conditioning regimen, which has not been associated with excessive cardiac toxicity. [43] [44] [45] [46] Mitoxantrone Significant cardiotoxicity has also been reported for the association of HD cyclophosphamide and HD mitoxantrone. 47, 48 HD mitoxantrone is commonly used as part of conditioning regimens not including HD cyclophosphamide, where its acute and long-term cardiac toxicity has been acceptable in a large series of patients. 7, 9, 49, 50 However, in one report, four out of six patients with no pre-existing cardiac disease experienced severe cardiac toxicity with two treatment-related deaths following administration of cyclophosphamide 2.4 g/m 2 (an 'intermediate' dose not associated with cardiac toxicity) and mitoxantrone 35-45 mg/m 2 . 47 In another study, administration of HD cyclophosphamide at the maximum tolerated dose (ie 200 mg/kg) divided into only two daily fractions may have played a role in determining a 25% incidence of CHF with one treatment-related death, besides the potential contribution of HD mitoxantrone in patients previously exposed to anthracyclines. 48 Overall, it is worth noting that considerable differences in cardiotoxicity profile were observed between combinations of cytarabine [39] [40] [41] [42] [43] [44] [45] or HD mitoxantrone, [47] [48] [49] [51] [52] [53] and HD cyclophosphamide for relatively minor differences in sequence and schedule of administration.
Other chemotherapeutic agents
Cardiotoxicity has seldom been reported for other cytotoxic drugs. HD thiotepa has been associated with a 5% cardiac toxicity in two studies, 54, 55 while other series did not confirm these findings. 8, 25 HD ifosfamide cardiotoxicity is reported in only two studies more than 20 years old. 56, 57 Anecdotal evidence is reported for HD carmustine-associated cardiac toxicity. 58 Recently, nonmyeloablative transplant regimens have been developed to exploit the graft-versus-tumor effect of allogeneic T-cell chimerism while reducing the toxicities associated with myeloablative conditioning. Particularly, the combination of HD melphalan and fludarabine has been used to condition patients with advanced hematologic malignancies. 59 HD melphalan has not been shown to be cardiotoxic, 7, 9, 25, 50, [60] [61] [62] [63] [64] with the exception of atrial fibrillation. [65] [66] [67] Fludarabine has also been rarely associated with cardiac dysfunction.
68 Surprisingly, after an initial report 59 of about 2.5% incidence of grade IV/V cardiac toxicity with this combination, this unexpected side effect has been confirmed in three other reports, with incidence up to 14% and outcomes variable from complete reversibility with standard medical treatment 69 to toxic deaths. 70, 71 These data clearly contrast with the reported rarity of cardiotoxicity with either agent individually. The mechanism of this unique toxicity is not known, as none of the patients had a history of cardiac disease and all of them had normal pre-transplant cardiac function and limited, if any, previous exposure to anthracyclines. The potential for cardiac toxicity of the HD melphalan and purine analogues association is highlighted also by the report of two grade IV/V cardiac toxicity in eight patients conditioned with HD melphalan and cladribine, which is not associated with cardiotoxicity when used as a single agent. 59 A summary of clinical cardiac toxicities associated with HD chemotherapy reported in the literature is listed in Table 1 .
Management of HD chemotherapy-associated cardiac toxicity
Diagnosis and treatment of HD chemotherapy-associated cardiac toxicity do not differ from the general approach to heart failure patients. Following administration of HD cyclophosphamide, nonspecific and transient electrocardiogram (ECG) abnormalities 10, 15, 18, 21 and left ventricular ejection fraction (LVEF) drops 10, 15, 23 have been recorded with no predictive value for the subsequent development of clinically relevant cardiotoxicity. These alterations are expected to return toward baseline within a few days or weeks in most cases. 8, 10, 15, 18, 21, 23 Therapy with diuretics should be started in the first instance. The addition of an angiotensin-converting enzyme inhibitor in case of ECG and/or two-dimensional echocardiogram (2D echo) evidence of impaired left ventricular contraction, the patient not being hypotensive, should be considered according to established guidelines. 73, 74 Oral dygoxin therapy may also be considered if heart failure persists. For HD cyclophosphamide-associated cardiac toxicity, experimental therapeutic interventions guided by clinical observations suggesting insights into the pathophysiology have also been conducted, but given the limited number of patients treated, they cannot be suggested as standard treatment. 20 Sustained or recurrent cardiac arrhythmias should be treated with appropriate antiarrhythmic agents and correction of possible precipitating factors, including sepsis and electrolyte disturbances. In the case of pericardial effusion, therapeutic aspiration is indicated if there is evidence of cardiac tamponade.
Finally, anecdotal reports indicate that late cardiomyopathy can be treated successfully by orthotopic cardiac transplantation. 75 
Risk factors and prevention of cardiac complications

Previous anthracycline exposure
Several studies, while showing a reduced LVEF in patients who had received anthracyclines in comparison with those who had not, failed to demonstrate a relationship between previous anthracycline exposure and development of cardiac toxicity following HD chemotherapy. 8, 10, 17, 18, 26, [76] [77] [78] [79] On the other hand, Steinherz et al 22 observed that HD cyclophosphamide-associated cardiac damage was most frequent in pediatric patients receiving cyclophosphamide X170 mg/kg or in those receiving X120 mg/kg who had received X100 mg/m 2 anthracyclines prior to transplant. Other authors found a trend towards significance also. 78, 80 Besides the inconsistent data in the literature, the potential contribution of previous anthracycline exposure to HD chemotherapy-associated cardiac toxicity should be reconsidered based upon recent insights about the progressive establishment of cardiac damage by anthracyclines. The long known assumption that the incidence of chronic cardiomyopathy is minimized by restricting the cumulative doxorubicin dose less than 400 mg/m 281 has been recently challenged. Also patients treated with a cumulative dose of Table 1 Clinical cardiac toxicity of single-agent HD chemotherapeutic agents and their combination anthracyclines below this threshold may experience subclinical or even clinical toxicity during or many years after therapy, if they are carefully monitored. [82] [83] [84] In particular, besides early-onset cardiac toxicity occurring within 1 year after the start of the anthracycline therapy, the incidence of late-onset cardiac effects (a year or longer after the completion of therapy) increases with longer follow-up. The incidence of echocardiographically measurable abnormality in systolic function increased from 14% after 4 to 6 years, to 24% after 7 to 9 years, to 38% after more than 10 years following exposure to anthracyclines in childhood. 82 Moreover, the incidence of severe cardiac dysfunction (fractional shortening o20%) was 0% at 4 to 6 years, 8% at 7 to 9 years and 15% after 10 years. 82 Consistent results have been reported also for adults. 83, 84 These findings suggest that a much larger number of cancer survivors than previously suspected, particularly survivors of childhood cancers, may have myocardial dysfunction as a result of anthracycline therapy.
In the light of these data, other strategies in addition to restriction of cumulative dose to reduce the cardiotoxic potential of anthracycline would be of interest. For example, the impact of anthracycline exposure on cardiac performance may be reduced by the application of cardioprotectors. 84 It is believed that the mechanism for anthracycline-associated cardiac toxicity is free radical formation with subsequent lipid peroxidation. Dexrazoxane, an antioxidant that functions by chelating iron, thereby reducing free radical formation, is the only cardioprotective drug approved by the Food and Drug Administration and recommended by the American Society of Clinical Oncology guidelines for patients receiving 4300 mg/m 2 doxorubicin. 85 Dexrazoxane consistently reduces the cardiotoxic effects of anthracyclines, allowing higher anthracycline doses to be used safely. 86 Complete protection, however, could not be achieved in most of the studies, and it is not known yet whether dexrazoxane provides any protection against late cardiovascular effects. Importantly, the weight of evidence shows that dexrazoxane does not affect the antitumor activity of anthracyclines. 86 Another strategy is the development of liposomal drug formulations of the anthracyclines. Liposomal encapsulation alters the tissue distribution of anthracyclines: tissues with a sinusoidal capillary system preferentially take up liposomes, so the continuous capillaries of cardiac muscles would reduce heart exposure to the drug. A further reduction in the risk of cardiac toxicity may be obtained by pegylated liposomal anthracyclines, whose pharmacokinetic is characterized by slow release of the drug avoiding high peak plasma concentration. Pegylated liposomal doxorubicin has shown similar efficacy with a significantly lower incidence of cardiac side effects compared with conventional doxorubicin. The long-term cardiac safety of these agents, however, is unknown yet. 87 
Radiation treatment
The heart volume exposed to irradiation influences the risk of cardiac toxicity. 88 Accordingly, prior radiation therapy to the mediastinum or left chest wall likely represents a risk factor. 28, 88 Moreover, radiation to the above fields appears to increase the cardiotoxicity of anthracyclines, although the two have different mechanisms of injury, 88 making patients with a history of both therapies possibly at higher risk for HD chemotherapy-associated cardiotoxicity.
The potential role of total body irradiation administered with HD cyclophosphamide (8-12 Gy) in increasing the risk for cardiac toxicity has been ruled out by several studies. 10, 19, 89, 90 Weight It has been suggested that cardiac toxicity can be avoided if HD cyclophosphamide is administered at a dose per m 2 rather than per kilogram. 16 In fact, children (who have a relatively smaller ratio of weight to body surface area than do adults) and obese patients, if treated on an mg/kg basis, would receive undertreatment and overtreatment, respectively. Optimal chemotherapy dosing in obese patients is one of the most controversial aspects of HD chemotherapy. Since obese individuals have altered pharmacokinetics (eg decreased clearance) for many medications including chemotherapeutic agents, [91] [92] [93] when compared with the nonobese, in several HD chemotherapy programs, there is a systematic approach to attenuation of chemotherapy doses in patients who are significantly above their ideal weight to avoid excessive toxicity. Indeed, association of obesity with cardiac toxicity can be spotted throughout the literature. 25, 50 However, no uniform clinical dosing guidelines have been established, leading to a marked variability among institutions according to the method of dose adjustment used. 94 As a practical approach, in our experience and that of other groups, reduction of HD cyclophosphamide dosage in patients whose actual weight exceeds by 420% the ideal weight is a safety measure that does not affect the efficacy of chemotherapy and minimizes the risk of toxicity. 7, 8, 95, 96 A formula to calculate adjusted weight has been suggested (adjusted weight is ideal weight plus 25% of the difference between actual and ideal weight) as a rule to calculate the dose of HD cyclophosphamide in these patients. 7, 8, 25, 96 Age It is commonly felt that patients over the age of 50 years may be at risk for future cardiac complications, especially if HD cyclophosphamide is part of the planned conditioning regimen. Patients up to 65-70 years of age are now being enrolled into HD chemotherapy or nonmyeloablative HSC transplantation programs. Some authors have found that older age represents a risk factor for the development of cardiovascular side effects, 28, 80 while others have not. 17, 70, 97, 98 It should be noted, however, that studies in which a positive correlation was found are those in which older patients (up to 65 years old) were included. Finally, an association of risk of CHF with age has been proposed for patients receiving anthracycline-based chemotherapy. 81, 84, 99 A summary of all suspected risk factors for HD chemotherapy-associated cardiac toxicity and relative preventive strategies is listed in Table 2 .
Predictive value of pre-HD chemotherapy cardiologic evaluation of patients
Preserved cardiac function is generally required for enrollment in clinical trials of HD chemotherapy. This is commonly defined as an LVEF 450% and no other significant cardiac disease. In at least seven studies, LVEF measured at rest was unable to predict future cardiac toxicity. 17, 28, 79, 80, 100, 104, 105 One of these studies also showed that measurement of cardiac reserve during exercise could not predict cardiac morbidity or mortality. 104 On the other hand, three studies reported a significant association between pre-transplant LVEF and cardiotoxicity 18, 54, 77 and two more described a trend in the same direction. 76, 101 However, measurement of LVEF before HD chemotherapy is of limited practical value: increased rates of minor cardiac events, rather than increased mortality due to severe cardiac toxicity, were recorded among patients with diminished (ie 50-54%) baseline LVEF, and 2/3 major cardiac events occurred in patients with normal LVEF. 100 Overall, resting LVEF measurement in every HD chemotherapy candidate is not recommended; 76,100 published evidence 7, 25, 76, 79, 100, 106 suggests that for patients undergoing front-line HD chemotherapy cardiologic evaluation including a detailed history, physical examination, chest X-ray and resting ECG is likely to be a sufficient screening tool to recognize candidates at high risk for cardiac complications. On the other hand, full pre-transplant evaluation with resting 2D echo of patients with history, symptoms or signs of cardiac disease or a history of anthracycline exposure and/or left chest wall radiotherapy remains prudent. Interestingly, it has been recently reported that resting ECG may be a powerful screening tool for prediction of HD chemotherapy-associated cardiac toxicity. QT dispersion analysis (ie the difference between the maximum and minimum QT intervals on standard 12-lead ECG), as a measure of cardiac electrical heterogeneity for identification of patients at increased risk for serious ventricular arrhythmias and sudden cardiac death, has been conducted in multiple disease states and showed promising results. QT dispersion and corrected QT interval (QTc) (ie QT interval corrected according to Bazett's formula) have been reported to predict acute heart failure following HD chemotherapy, particularly HD cyclophosphamide-containing regimens, more effectively than 2D echo parameters. 39, 98, 107 It can be speculated that increases in QT dispersion and QTc may reflect local or multifocal abnormalities of cardiac muscle that can be detected only by ECG. Moreover, these ventricular repolarization indices can be easily calculated at most hospitals and certainly deserve further investigation in a larger number of patients.
HD chemotherapy in patients with subclinical cardiac dysfunction
In light of the limited predictive value of cardiologic evaluation, exclusion from HD chemotherapy programs of patients with slightly depressed (ie subclinical) cardiac function as measured by LVEF should be reconsidered. As a matter of fact, several studies suggest that such patients can tolerate HD chemotherapy. In the report by Hertenstein et al, 100 none of the eight patients with an LVEF o50% experienced cardiac toxicity. Three women with an LVEF o50% (4772%) underwent a sequence of HD cyclophosphamide (5 g/m 2 ), HD melphalan (140 mg/m 2 ) and HD thiotepa (900 mg/m 2 ) without any clinical cardiotoxicity. 102 In this series of patients, however, the patient with the lowest baseline LVEF (33%) had CHF, although easily managed. 102 Another report showed that patients undergoing HD chemotherapy with LVEF o50% (range 49-39%) do not necessarily experience more pronounced cardiac deterioration than patients starting from LVEF 450% when treated with different HD chemotherapy regimens, including HD cyclophosphamide. 90 Six patients with initial LVEF o50% (4277%) were given enalapril and they underwent conditioning regimens containing HD cyclophosphamide X120 mg/kg even twice with no cardiac function deterioration at a median follow-up of 18 Table 2 Risk factors for HD chemotherapy-associated cardiac toxicity
Risk factor Prevention Refs.
Dosage
Total dose pmaximum-tolerated dose as single agent 4, 5, [7] [8] [9] 25 Schedule of administration Adopt the least cardiotoxic schedule (eg multifractionated schedule for HD cyclophosphamide) 4, 5, [7] [8] [9] 25 Concomitant administration of other chemotherapeutic agents Avoid reportedly cardiotoxic associations or treatment schedules 10, 12, 14, 15, [39] [40] [41] [42] History of radiation therapy to the mediastinum or left chest wall
Thorough pre-HD chemotherapy cardiologic evaluation including 2D echo 28, 88 History of anthracycline exposure Thorough pre-HD chemotherapy cardiologic evaluation including 2D echo restriction of total anthracycline exposure to o400 mg/m 2 use of cardioprotectors (ie dexrazoxane) use of liposomal formulations of anthracyclines 22, 78, 80, [84] [85] [86] [87] Older High-dose therapy cardiac toxicity P Morandi et al months. 103 Finally, in 11 patients whose pre-transplant LVEF was o50%, no signs of heart failure were recorded at prolonged follow-up after HSC transplantation. 79 Therefore, patients with subclinical impairment of cardiac function should not be excluded a priori from HSC transplantation if otherwise indicated, but thorough cardiologic evaluation and monitoring are warranted.
New diagnostic strategies to detect and monitor HD chemotherapy-associated cardiac toxicity
In addition to overt clinical impairment of cardiac function, studies have also reported subclinical cardiotoxicity, that is, any alteration of functional and/or biochemical values from baseline measured by different diagnostic techniques. Markers of subclinical cardiotoxicity with predictive value for subsequent development of clinical cardiac toxicity would allow identification of patients who need careful cardiologic monitoring and therapy to prevent major complications. This is relevant not only for patients undergoing HD chemotherapy but also for HD chemotherapy candidates who receive anthracycline-based chemotherapy, as development of cardiac failure several months or years after the last administration 82, 99, 108, 109 is preceded by treatable, asymptomatic but progressive cardiac dysfunction. 110 Echocardiography/radionuclide angiocardiography Two major Consensus Guidelines 111, 112 recommended LVEF estimation with radionuclide angiocardiography or 2D echo for detecting/monitoring chemotherapy-associated cardiotoxicity during and shortly after the end of treatment. Despite its wide clinical use, including HD chemotherapy, 10, 15, 23, 50, 90, 113, 114 LVEF measurement is a relatively insensitive technique for detecting drug-induced cardiotoxicity at an early stage. However, traditional 2D echo allows measurement of various parameters of both systolic and diastolic function, anatomic dimensions and afterload. As diastolic modifications from baseline values occur earlier in other clinical settings, 110 there has been an increasing interest in measuring diastolic, rather than systolic, parameters to detect subclinical cardiac toxicity in patients receiving chemotherapy. Indeed, one recent study suggests that indexes of early diastolic function are predictive for the early detection of anthracycline-associated cardiac toxicity. 115 In the HD chemotherapy setting, single-agent HD cyclophosphamide resulted in a transient but significant E/A (early and atrial diastolic velocities) ratio change in 5/16 8 and 1/21 patients, 89 without changes in traditional systolic indexes, suggesting that reversible reduction of left ventricular diastolic compliance may represent the initial sign of reversible cardiac dysfunction following HD cyclophosphamide administration. 8 However, 2D echo evaluation of both systolic and diastolic indexes potentially suffers from inter-and intraobservatory variability as well as changes in hemodynamic conditions such as heart rate, preload and afterload, which may vary over the course of treatment. 110 To diminish the confounding effect of varying hemodynamic conditions, recently developed ultrasound techniques such as Doppler Tissue Imaging and Color M-Mode mitral flow propagation study intrinsic diastolic myofiber properties (relaxation and elastic recoil). 110 More significant (435%) and earlier changes of these indexes from basal values than standard diastolic indexes (E/A ratio and isovolumetric relaxation time) have been recorded in patients treated with anthracycline-based chemotherapy (GM Benvenuto, unpublished data). These promising techniques warrant further investigation in larger cohorts of patients, as their advantages include applicability to virtually all patients, including those with poor quality echogenic windows, and a good intra-and interobservatory variability; however, specific skills and experience are required to perform and interpret these new echo technologies.
Circulating markers
Troponins are actin-associated regulatory proteins, not normally present in serum. Therefore, an increase in serum cardiac troponin (cTn) level is a sensitive and specific marker for myocardial necrosis. 116 Cardiac troponins (cTnT and cTnI, the diagnostic and prognostic values of the two isoforms are clinically identical) are released within 4 to 12 h following an episode of myocardial necrosis with a peak value 12 to 48 h following the injury. cTn's have recently been applied to the early detection of chemotherapy-induced cardiac toxicity, 117 where they have shown predictive value for long-term, cumulative cardiac damage by anthracycline. 118 In the HD chemotherapy setting, plasma cTnI levels were measured for up to 72 h after every HD chemotherapy cycle (often containing anthracyclines) with repeated 2D echo examination for up to 7 months after therapy in a large series of patients. Patients with cTnI levels o0.4 ng/ml had a small median drop in LVEF at 3 months follow-up examination, which subsequently normalized, whereas those with cTnI levels 40.4 ng/ml had a greater decrease in LVEF (16%), which was still evident at later follow-up. 97 In the latter group, a close correlation between maximally elevated cTnI levels and decrease of LVEF was also observed. In a recent update of their series, the same authors could stratify patients at different risk of cardiac events following HD chemotherapy based on even minimal elevations of cTnI levels recorded soon after chemotherapy and 1 month later. 119 However, the vast majority of patients showing a rise in cTnI received high-dose epirubicin, while cTnI measurements after single-agent HD cyclophosphamide (7 g/m 2 ) in 49 patients of these series were not reported. 97 In our experience and that of other groups, serial plasma measurements of cTnI or cTnT after single-agent HD cyclophosphamide were uniformly negative. 8, 89 Differences in pathophysiological mechanisms underlying anthracycline-and HD cyclophosphamide-associated cardiac toxicity, respectively, may explain the difference. Since cTn's are markers of myocardial cell necrosis with plasma levels paralleling the extent of damage, they primarily detect toxicity from chemotherapeutic agents directly damaging myocardial cell membrane and not from those primarily affecting endothelium and/or interstitium, as it has been proposed for HD cyclophosphamide. 8 Therefore, the High-dose therapy cardiac toxicity P Morandi et al absence of cTn elevations following single-agent HD cyclophosphamide possibly reflects the absence of direct membrane damage, as further suggested by a study using indium-111 monoclonal antimyosin antibody scintigraphy, which can detect small areas of myocardial damage or necrosis in a variety of diseases binding intracellular myosin after sarcolemmal disruption. The scan was negative in 14/14 patients treated with the HD cyclophosphamidecontaining regimen STAMP-V (cyclophosphamide, thiotepa and carboplatin). 120 Natriuretic peptides (atrial natriuretic peptide, ANP and brain natriuretic peptide, BNP) are cardiac hormones released in response to atrial or ventricular load-induced stresses, and their plasma levels are inversely correlated with measures of cardiac function. 121 Existing data suggest a strong correlation between natriuretic peptide measurement and myocardial dysfunction following standard dose anthracycline chemotherapy. 122, 123 Importantly, unlike cTn's, BNP elevation may reflect chemotherapy-associated diastolic abnormalities 123, 124 and the level may be increased by myocardial stress without necrosis, 125 thus potentially increasing their sensitivity over that afforded by cTn's. In the HD chemotherapy setting, patients who developed clinical heart failure exhibited elevated plasma BNP level in several measurements before the onset of signs/symptoms, although lesser elevations, and only on a single measurement were detected also in patients who did not experience cardiac toxicity. 126 In another series of patients, elevations of natriuretic peptides were observed on days 1 and 14 following HD chemotherapy, but neither peak was predictive of cardiac toxicity. 127 Overall, the utility and applicability of new 2D echobased techniques have not been determined yet, and their use should be restricted to specific clinical studies addressing the risk of HD chemotherapy-associated cardiotoxicity in patients with a history of anthracycline exposure. The technically simpler dosage of circulating markers is partly countered by the lack of knowledge about optimal timing of measurement, and its potential use as a diagnostic and predictive tool also remains investigational. However, the reported potential for cTnI to stratify patients at risk for cardiac complications following anthracyclinecontaining HD chemotherapy 119 warrants further investigation. Finally, dosage of cardiac markers in patients undergoing conditioning regimens associated with unexpected and completely unexplained cardiac toxicity 59,69-71 may provide insights into the underlying pathophysiology.
Currently available tools for early detection and monitoring of chemotherapy-associated cardiac toxicity with their present limitations and future perspectives are summarized in Table 3 .
Conclusions
Conflicting data were found in the literature about all aspects of HD chemotherapy-associated cardiac toxicity. Several reasons may account for the variability observed, particularly differences in conditioning regimens, patient selection and application of different grading systems. 76, 128, 129 This makes it difficult to compare results between studies and to identify predisposing risk factors. However, based on published evidence and our own personal experience, some general features have been identified. HD cyclophosphamide is the agent most frequently associated with cardiac toxicity. Dosage, 16 application regimens 18 and simultaneous use of other cytotoxic drugs. 10, 12, 14, 15, 20, [39] [40] [41] [42] 47, 48, 107 have emerged as risk factors. Although once common, clinically significant cardiac complications now occur in less than 5% of patients. 7, 8, 25, 106, 130 Nonetheless, grade IV cardiac toxicity 39, 48 and toxic deaths 42, 47, 48 are still being recorded. Moreover, cardiotoxicity has emerged as an unexpected side effect of HD melphalan and fludarabine Table 3 Noninvasive strategies for early detection and monitoring of cardiac toxicity High-dose therapy cardiac toxicity P Morandi et al administration. 59, [69] [70] [71] Pharmacokinetic and pharmacodynamic studies have provided little insight into the mechanisms underlying HD chemotherapy-associated cardiac toxicity. As of today, no widely accepted parameter before or during HD chemotherapy exists to predict which patients will develop cardiac dysfunction. Therefore, a risk-adapted pre-transplant cardiologic evaluation should be adopted, with 2D echo evaluation limited to patients with a history of cardiac disease or pre-transplant exposure to anthracyclines and/or radiation therapy to the mediastinum or left chest wall. An important finding of our retrospective analysis is that patients with a slightly depressed cardiac function (LVEF 40-49%) can undergo HD chemotherapy and HSC transplantation with acceptable risk of cardiac toxicity 79, 90, 100, 102, 103 as long as it represents the only potentially curative treatment option available.
ECG-39,98,107 and 2D echo-based diagnostic techniques 8, 89, 110 and circulating markers 8, 97, 119, 123 are being investigated as candidate highly sensitive and specific tools to identify patients at risk for cardiac complications from HD chemotherapy and to permit early diagnosis. 110 Finally, the few data available about long-term cardiologic follow-up of patients after HD chemotherapy and HSC transplantation suggest that HD chemotherapy does not cause per se late development of cardiac toxicity, 5, 79, 90 although subclinical alteration of cardiac performance may last long. 50, 90, 109, [131] [132] [133] [134] This is particularly important for the proportion of patients who may need a potentially cardiotoxic agent after HD chemotherapy for their relapsing disease. 135 
